Real-world practice of obstetricians in respect of assays for antiphospholipid antibodies

被引:1
|
作者
Sugiura-Ogasawara, Mayumi [1 ]
Atsumi, Tatsuya [2 ]
Yamada, Hideto [3 ]
Kitaori, Tamao [1 ]
Ozaki, Yasuhiko [1 ]
Katano, Kinue [1 ]
Murashima, Atsuko [4 ]
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Nagoya, Aichi 4678601, Japan
[2] Hokkaido Univ, Grad Sch Med, Dept Rheumatol Endocrinol & Nephrol, Sapporo, Hokkaido, Japan
[3] Kobe Univ, Grad Sch Med, Dept Obstet & Gynecol, Kobe, Hyogo 657, Japan
[4] Natl Ctr Child Hlth & Dev, Ctr Maternal Fetal Neonatal & Reprod Med, Tokyo, Japan
关键词
Antiphospholipid antibody; lupus anticoagulant; obstetric antiphospholipid syndrome; recurrent pregnancy loss; survey; RECURRENT PREGNANCY LOSS; ASPIRIN PLUS HEPARIN; LUPUS ANTICOAGULANT; ANTICARDIOLIPIN ANTIBODIES; WOMEN; AUTOANTIBODIES; PREDICTOR; RECOGNIZE; UPDATE; TRIAL;
D O I
10.3109/14397595.2015.1023978
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. The international classification criteria (CC) for definite antiphospholipid syndrome (APS) recommend confirmation of the sustained presence, for at least 12 weeks, of both lupus anticoagulant (LA), as determined by aPTT and RVVT, and anti beta 2glycoprotein I (beta 2GPI) or anticardiolipin (aCL) IgG and/or IgM. However, it remains unclear whether obstetricians comply with the aforementioned CC for the diagnosis of APS in daily clinical practice. We performed a nationwide survey to examine the attitudes of Japanese obstetricians toward the use of assays for antiphospholipid antibodies (aPLs). Methods. A questionnaire was sent to 2,700 obstetric facilities where maternity checkups are car-ried out. The types of assays conducted for aPLs, ascertainment of persistence of the antibodies for at least 12 weeks, and the cutoff points used for the assays were examined. Results. Of the facilities surveyed, 61.5% carried out the assay(s) only once. In regard to the type of assay performed, 97.1% carried out the assay for aCL IgG and/or beta 2GPI-dependent aCL, while 67.9% performed the LA-aPTT and/or LA-RVVT assay. Only 8.8% carried out assays for both LA. As for the cutoff points used, 98% of the facilities used lower cutoff points described in the manufacturers' manuals rather than the cutoff values recommended in the CC. Conclusion. Thus, only a limited number of facilities adhered precisely to the CC for the diagnosis of APS. Inappropriate treatment and unnecessary expense are potentially major concerns when facilities overdiagnose APS using lower cutoff points or without ascertaining the persistence of the antibodies for at least 12 weeks. On the other hand, some patients miss the opportunity to be treated for APS because of the absence of testing for LA.
引用
收藏
页码:883 / 887
页数:5
相关论文
共 50 条
  • [1] Antiphospholipid antibodies in practice
    Miyara, M.
    Diemert, M-C.
    Amoura, Z.
    Musset, L.
    REVUE DE MEDECINE INTERNE, 2012, 33 (04): : 176 - 180
  • [2] Plasma Antiphospholipid Antibodies Effects on Activated Partial Thromboplastin Time Assays
    Yao, Ke
    Zhang, Lingyun
    Zhou, Hang
    Tang, Ning
    Li, Dengju
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2017, 354 (01) : 22 - 26
  • [3] Antiphospholipid antibodies: Basic immunology and assays
    Schultz, DR
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 1997, 26 (05) : 724 - 739
  • [4] Solid Phase Assays for Antiphospholipid Antibodies
    Devreese, Katrien M. J.
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2022, 48 (06) : 661 - 671
  • [5] Real-World Practice of Hypofractionated Radiotherapy in Patients With Invasive Breast Cancer
    Chen, Fang
    Hui, Timothy S. K.
    Ma, Lingyu
    Nong, Yaqing
    Han, Ying
    Jing, Haiman
    Lee, Eric K. W.
    Xu, Zhiyuan
    Fu, Pingfu
    Chang, Amy Tien Yee
    Hsue, Victor
    Kong, Feng-Ming Spring
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [6] Both IgG and IgM anti-beta2 glycoprotein I antibodies assays are clinically useful to the antiphospholipid syndrome diagnosis
    Li, R.
    Daguzan, M.
    Vandermijnsbrugge, F.
    Gyling, M.
    Cantinieaux, B.
    ACTA CLINICA BELGICA, 2014, 69 (06) : 433 - 438
  • [7] Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome
    Persijn, Lies
    Decavele, An-Sofie
    Schouwers, Sofie
    Devreese, Katrien
    THROMBOSIS RESEARCH, 2011, 128 (06) : 565 - 569
  • [8] Abnormal optical waveform profiles in coagulation assays from patients with antiphospholipid antibodies
    Su, Z
    Braun, PJ
    Klemp, KF
    Baker, KR
    Thames, EH
    Ortel, TL
    BLOOD COAGULATION & FIBRINOLYSIS, 2002, 13 (01) : 7 - 17
  • [9] Validation of a New Panel of Automated Chemiluminescence Assays for Anticardiolipin Antibodies in the Screening for Antiphospholipid Syndrome
    Janek, D.
    Slavik, L.
    Ulehlova, J.
    Krcova, V.
    Hlusi, A.
    Prochazkova, J.
    CLINICAL LABORATORY, 2016, 62 (07) : 1309 - 1315
  • [10] Impact of fampridine on quality of life: clinical benefit in real-world practice
    Belen Marzal-Alfaro, Maria
    Martin Barbero, Maria Luisa
    Garcia Dominguez, Jose M.
    Romero-Delgado, Fernando
    Martinez Gines, Maria Luisa
    Herranz, Ana
    Sanjurjo-Saez, Maria
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2018, 25 (03) : 138 - 143